Perceptions of the Benefits and Risks of Novel Therapies for Type 1 Diabetes: A Qualitative Study
Despite concerns about the risks and drawbacks of novel therapies, most participants reported that they would consider trying disease-modifying and cell replacement therapies. There is no substitute for consulting people living with or caring for someone with type 1 diabetes when considering new therapies with novel risks and benefits.
Authors
- Peter Senior (ORCID: https://orcid.org/0000-0003-1033-8673)
- Marjana Marinac (ORCID: https://orcid.org/0000-0002-5082-6201)
- Cooper Bussberg (ORCID: https://orcid.org/0000-0002-7854-3596)
- Linda Anne DiMeglio (ORCID: https://orcid.org/0000-0002-8033-6078)
- Richard Mellor (ORCID: https://orcid.org/0000-0002-7603-5256)
- Kelley Myers (ORCID: https://orcid.org/0000-0002-0936-5677)
- Jennifer L. Sherr (ORCID: https://orcid.org/0000-0001-9301-3043)
- Stephen R. Karpen (ORCID: https://orcid.org/0000-0002-9063-8010)
- C.M. Mansfield
Institutions
- University of Alberta (CA)
- Breakthrough Institute (US)
- Riley Hospital for Children (US)
- Yale University (US)
- Breakthrough (US)
- RTI Health Solutions (US)
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Diabetes Therapy
- Published
- 2025-09-04
- DOI
- https://doi.org/10.1007/s13300-025-01783-y
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00